Cutler Group’s ANI Pharmaceuticals ANIP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-400
Closed -$3K 4372
2017
Q4
$3K Sell
400
-900
-69% -$56K ﹤0.01% 3912
2017
Q3
$3K Hold
1,300
﹤0.01% 4727
2017
Q2
$2K Sell
1,300
-8,300
-86% -$400K ﹤0.01% 5422
2017
Q1
$11K Sell
9,600
-27,900
-74% -$1.57M ﹤0.01% 3919
2016
Q4
$106K Sell
37,500
-20,600
-35% -$1.26M ﹤0.01% 1856
2016
Q3
$599K Buy
58,100
+21,500
+59% +$1.34M 0.03% 528
2016
Q2
$188K Buy
36,600
+34,000
+1,308% +$1.65M 0.01% 1159
2016
Q1
$1K Sell
2,600
-15,700
-86% -$533K ﹤0.01% 5874
2015
Q4
$38K Buy
+18,300
New +$788K ﹤0.01% 2749

Other funds holding ANIP

Cutler Group's ANIP Position: Q2 2018 in Review

Cutler Group sold out of ANI Pharmaceuticals (ANIP) in Q2 2018, closing a stake of 100 shares — an estimated $5K sold.

Cutler Group first reported a position in ANIP in Q4 2015 and held it in 9 quarters. The position peaked at $314K in Q1 2017. 184 funds tracked by Wall St. Rank hold ANIP as of Q2 2018.

  • Cutler Group reported no remaining ANI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Cutler Group sold 100 ANI Pharmaceuticals shares in Q2 2018, an estimated $5K.
  • Cutler Group first reported a position in ANI Pharmaceuticals in Q4 2015 and held it in 9 quarters.
  • Cutler Group's ANI Pharmaceuticals position peaked at $314K in Q1 2017.
  • 184 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.